Reprogenesis

Reprogenesis was a biotechnology company specializing in the field of regenerative medicine and tissue engineering. Founded in 1996, the company focused on developing autologous cell-based therapies to repair or replace damaged tissues, particularly in the urological and gynecological fields. Its core technology involved the delivery of specific cell types, such as chondrocytes or muscle cells, within a biocompatible polymer to promote localized tissue growth. The company's lead clinical programs targeted conditions like vesicoureteral reflux and urinary incontinence. In 2000, Reprogenesis participated in a high-profile three-way merger with Creative BioMolecules and Ontogeny to form Curis. This merger aimed to combine diverse regenerative technologies into a single platform for treating a wide range of degenerative diseases.